Anthem Blue Cross and Blue Shield | CommercialMarch 1, 2025
Clinical Criteria updates for specialty pharmacy are available
Updates
Effective for dates of service on and after June 1, 2025, the following Clinical Criteria will apply. Services that were previously covered may now be found not medically necessary.
Prior authorization
Prior authorization of these specialty pharmacy drugs is managed by Anthem except where the drug is used for oncology treatment. Oncology drugs require prior authorization by Carelon Medical Benefits Management, Inc. This applies to members with both PPO and HMO.
Access Clinical Criteria information here.
Document number | Description |
CC‑0130 | Imfinzi (durvalumab) |
CC‑0058 | Octreotide Agents |
CC‑0185 | Oxlumo (lumasiran) |
CC‑0256 | Rivfloza (nedosiran) |
CC‑0276 | Tryngolza (olezarsen) |
Carelon Medical Benefits Management, Inc. is an independent company providing utilization management services on behalf of the health plan.
Anthem Blue Cross and Blue Shield is the trade name of Anthem Health Plans of Virginia, Inc. Anthem Blue Cross and Blue Shield, and its affiliate HealthKeepers, Inc., serving all of Virginia except for the City of Fairfax, the Town of Vienna, and the area east of State Route 123, are independent licensees of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc.
VABCBS-CM-077846-25
PUBLICATIONS: March 2025 Provider Newsletter
To view this article online:
Or scan this QR code with your phone